Terms: = Leukemia AND FBXO11, MGC44383, 80204, ENSG00000138081, Q86XK2, VIT1, UG063H01, PRMT9, FLJ12673, FBX11
5 results:
1. Targeting prmt9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity.
Dong H; He X; Zhang L; Chen W; Lin YC; Liu SB; Wang H; Nguyen LXT; Li M; Zhu Y; Zhao D; Ghoda L; Serody J; Vincent B; Luznik L; Gojo I; Zeidner J; Su R; Chen J; Sharma R; Pirrotte P; Wu X; Hu W; Han W; Shen B; Kuo YH; Jin J; Salhotra A; Wang J; Marcucci G; Luo YL; Li L
Nat Cancer; 2024 Apr; 5(4):601-624. PubMed ID: 38413714
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of the CtBP complex and fbxo11 enhances MHC class II expression and anti-cancer immune responses.
Chan KL; Gomez J; Cardinez C; Kumari N; Sparbier CE; Lam EYN; Yeung MM; Garciaz S; Kuzich JA; Ong DM; Brown FC; Chan YC; Vassiliadis D; Wainwright EN; Motazedian A; Gillespie A; Fennell KA; Lai J; House IG; Macpherson L; Ang CS; Dawson SJ; Beavis PA; Wei AH; Burr ML; Dawson MA
Cancer Cell; 2022 Oct; 40(10):1190-1206.e9. PubMed ID: 36179686
[TBL] [Abstract] [Full Text] [Related]
3. Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.
Yoshida M; Tomizawa D; Yoshimura S; Osumi T; Nakabayashi K; Ogata-Kawata H; Ishiwata K; Sato-Otsubo A; Kimura Y; Ito S; Matsumoto K; Deguchi T; Kiyokawa N; Yoshioka T; Hata K; Kato M
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1545. PubMed ID: 34472720
[TBL] [Abstract] [Full Text] [Related]
4. fbxo11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome.
Schieber M; Marinaccio C; Bolanos LC; Haffey WD; Greis KD; Starczynowski DT; Crispino JD
Blood Cancer J; 2020 Oct; 10(10):98. PubMed ID: 33024076
[TBL] [Abstract] [Full Text] [Related]
5. Identification of a tumor suppressor network in T-cell leukemia.
Nagel S; Pommerenke C; Meyer C; Kaufmann M; MacLeod RAF; Drexler HG
Leuk Lymphoma; 2017 Sep; 58(9):2196–2207. PubMed ID: 28142295
[TBL] [Abstract] [Full Text] [Related]
